Insider buying last 90 days
No open-market insider purchases were filed for ETON in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ETON insider filing, plotted on the chart in Gekko.Open ETON in Gekko
NASDAQ: ETON
Eton Pharmaceuticals (ETON) Stock Analysis & Forecast
Oct 12 close
$55.25+0.04 (+0.1%)
Gekko Brief
Oct 12 closeEton Pharmaceuticals closed at $55.25 on 12 October 2026, +0.1% on the day. The price sits between the 50-day ($55.72) and 200-day ($33.27) moving averages, inside a 52-week range of $14.27 to $66.37. The GekkoIndex reads 59.3, in the Neutral zone, down 1.5 points over five sessions. Gekko Fair Value is $61.72, so the price is 10.5% below it.
The next earnings report is due on 5 November 2026, 24 days away (after close). Over the last 8 reports the company beat the earnings estimate 3 times, with an average move of 12.8% across the report. Seasonally, the next 20 trading days from this point averaged +8.7% over the last 5 years, rising in 4 of them.
3 firms rate the stock: 3 buy, 0 hold and 0 sell, with a consensus target of $71.00. A typical daily move is about 6.4%, and a typical 20-day move about 12%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (earnings risk).
A plain summary of the figures as of the Oct 12, 2026 close.
Eton Pharmaceuticals price vs fair value
Close $55.25200-day averageGekko Fair Value $61.72
Eton Pharmaceuticals quick facts
- Market cap
- $1.51B
- P/E ratio
- 136.9
- Forward P/E
- 23.9
- EPS, TTM
- $0.40
- Revenue, TTM
- $105.6M
- Profit margin
- 12%
- Dividend yield
- —
- Beta
- 0.90
- Volume
- 436,784 avg 612,705
- 1-year return
- +172.4%
- Typical daily move
- ±6.4%
- Typical 20-day move
- ±12%
- 50-day average
- $55.72
- 200-day average
- $33.27
- Next earnings
- Nov 5 after close
- Shares outstanding
- 28.58M
Eton Pharmaceuticals swing-trade checklist
Eton Pharmaceuticals scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $55.25 sits between the 50-day ($55.72) and 200-day ($33.27) averages, or the averages disagree.
See the chart - GekkoIndexmixed
59.3, Neutral
Reading 59.3 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
10.5% below
Price is 10.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+8.7% on average
From this point in the calendar, the next 20 trading days averaged +8.7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Eton Pharmaceuticals stock chart and price history
Eton Pharmaceuticals closed at $55.25 on Oct 12, 2026, +172.4% over the past year, inside a 52-week range of $14.27 to $66.37.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −3.2%
- 3 months
- +47.3%
- 6 months
- +112.1%
- 1 year
- +172.4%
The full ETON chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ETON in Gekko
Follow Eton Pharmaceuticals through every session
Put ETON on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ETON in GekkoFree for 7 days. No credit card required.
Eton Pharmaceuticals GekkoIndex: the smart money zone
Eton Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.3, in the Neutral zone, down 1.5 points over five sessions.
59.3Neutral
Down 1.5 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 23 | +5.1% | +5.9% |
| Accumulation | 162 | +1.0% | +5.5% |
| Neutral (current zone) | 374 | +2.2% | +10.0% |
| Distribution | 111 | +4.1% | +14.3% |
| Selling | 12 | +1.0% | +15.3% |
Average ETON share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ETON price, zone by zone.Track ETON in Gekko
Is Eton Pharmaceuticals stock overvalued? Gekko Fair Value
Eton Pharmaceuticals trades 10.5% below Gekko Fair Value of $61.72, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Eton Pharmaceuticals shares are worth, recalculated every trading day.
$61.72
Gekko Fair Value, Oct 10, 2026
10.5% Undervalued
At the end of Aug 2026 the price was 2.7% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ETON in Gekko
Eton Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Eton Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ETON were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ETON, plotted on the chart in Gekko.Open ETON in Gekko
Buybacks
Eton Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2023
- $181K
- As a share of market cap
- 0.01%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
1of the funds Gekko tracks holds ETON.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Eton Pharmaceuticals earnings: next date and track record
Eton Pharmaceuticals reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- $0.31
- Revenue estimate
- $41.98M
3 of 8reports beat the EPS estimate
±12.8%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 13, 2026 AI summary
- What they said
- Eton Pharmaceuticals reported record Q2 2026 revenue of $37.6 million, up 99% year-over-year, driven by HEMANGEOL relaunch and pediatric endocrinology franchise. Adjusted EBITDA reached $16.2 million (43% margin) vs. $3.6 million (16%) prior year. Strategic moves included acquiring U.S. rights to IMPAVIDO, licensing ASN-001, and receiving Fast Track designation for Amglidia. HEMANGEOL transitioned 95% of patients to new distribution model ahead of schedule.
- Guidance
- Full-year 2026 revenue guidance raised to exceed $145 million, up from prior guidance of $120 million. Adjusted EBITDA margin guidance raised to exceed 35%, up from 30%, with long-term target above 50%.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 13, 2026 | $0.35 est $0.19 | $37.59M est $27.11M | +41.6% |
| May 14, 2026 | $0.14 est $0.14 | $24.27M est $22.31M | −1.8% |
| Mar 19, 2026 | $0.19 est $0.18 | $21.28M est $19.98M | +17.4% |
| Nov 6, 2025 | −$0.07 est $0.16 | $22.46M est $20.47M | −12.2% |
| Aug 7, 2025 | −$0.10 est −$0.01 | $18.93M est $20.47M | +12.3% |
| May 13, 2025 | $0.07 est $0.09 | $17.28M est $15.13M | −1.3% |
| Nov 12, 2024 | $0.02 est −$0.01 | $10.32M est $10.53M | +9.2% |
| Aug 8, 2024 | −$0.12 est −$0.07 | $9.07M est $9.69M | +6.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Eton Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Eton Pharmaceuticals is $71.00, +28.5% from the last close, from 3 firms rating the stock in the last 90 days.
$71.00consensus 12-month target, +28.5% from the last close
Now $55.25Avg $71.00
Low $60High $70
Each firm’s latest rating in the last 90 days: 3 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 1 | H.C. Wainwright | $70 | +26.7% |
| Aug 13 | Craig-Hallum | $62 | +12.2% |
| Aug 11 | H.C. Wainwright | $65 | +17.6% |
| Jul 30 | Canaccord Genuity | $60 | +8.6% |
| Jul 28 | Craig-Hallum | $62 | +12.2% |
+10.0%average 20-day move after past Neutral readings
+8.7%average move over the next 20 trading days in the last 5 years
±6.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Eton Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Eton Pharmaceuticals averaged +8.7% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.5% | 4 of 5 |
| Next 10 trading days | +0.5% | 2 of 5 |
| Next 15 trading days | +11.4% | 4 of 5 |
| Next 20 trading days | +8.7% | 4 of 5 |
| Next 30 trading days | +8.0% | 2 of 5 |
For scale, ETON’s typical 20-trading-day move in either direction is about 12%.
Eton Pharmaceuticals market cap and key statistics
Eton Pharmaceuticals’s market cap is $1.51B, with a P/E ratio of 136.9 and revenue of $105.6M over the last twelve months.
Valuation
- Market cap
- $1.51B
- P/E ratio
- 136.9
- Forward P/E
- 23.9
- EPS, TTM
- $0.40
- Gekko Fair Value
- $61.72
Trading
- Volume
- 436,784
- Avg volume, 20 days
- 612,705
- 52-week high
- $66.37
- 52-week low
- $14.27
- Shares outstanding
- 28.58M
Financials
- Revenue, TTM
- $105.6M
- Profit margin
- 12%
- Return on equity
- 36%
- Quarterly earnings growth, YoY
- −12.6%
Risk and income
- Beta
- 0.90
- Typical daily move
- ±6.4%
- Typical 20-day move
- ±12%
Eton Pharmaceuticals stock news this week
Coverage of Eton Pharmaceuticals this week reads neutral: 0 positive, 4 neutral and 0 negative headlines.
- Form 4 Eton Pharmaceuticals Inc For: 11 October By Investing.comInvesting.com Nigeria, Oct 11
- Eton Pharmaceuticals CBO David Krempa sells $229k in stockInvesting.com, Oct 11
- Financial Survey: Eton Pharmaceuticals (NASDAQ:ETON) vs. Cronos Group (NASDAQ:CRON)Defense World, Oct 8
- ETON Stock Surges 108% in Six Months: Here's What You Need to KnowZacks Investment Research, Oct 7
- To cover stock-grant vesting, Eton Pharmaceuticals (ETON) officer proposes selling 4,166 shares.Stock Titan, Oct 6
- Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells $229,421.62 in StockMarketBeat, Oct 6
Eton Pharmaceuticals peers
Eton Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Eton Pharmaceuticals stock FAQ
What is Eton Pharmaceuticals’s market cap?
Eton Pharmaceuticals’s market cap is $1.51B at the Oct 12, 2026 close of $55.25, with 28.58M shares outstanding. The shares trade on a P/E ratio of 136.9.
What is the Eton Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Eton Pharmaceuticals is $71.00, +28.5% from the last close. Of the 3 firms that rated the stock in the last 90 days, 3 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Eton Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Eton Pharmaceuticals is undervalued: the Oct 12, 2026 close of $55.25 is 10.5% below Gekko Fair Value of $61.72. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Eton Pharmaceuticals report earnings next?
Eton Pharmaceuticals is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of $0.31 per share on revenue of $41.98M. Eton Pharmaceuticals beat the earnings estimate in 3 of its last 8 reports, moving 12.8% on average across the report.
What is Eton Pharmaceuticals’s 52-week high and low?
Eton Pharmaceuticals’s 52-week high is $66.37 and its 52-week low is $14.27; it closed at $55.25 on Oct 12, 2026, +172.4% over the past year.
Is Eton Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Eton Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.